Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP455475.RALu8wx2WMMh6xstlcVhSGuyUcjHF8XV7EnKrtnlhzjVI130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP455475.RALu8wx2WMMh6xstlcVhSGuyUcjHF8XV7EnKrtnlhzjVI130_assertion type Assertion NP455475.RALu8wx2WMMh6xstlcVhSGuyUcjHF8XV7EnKrtnlhzjVI130_head.
- NP455475.RALu8wx2WMMh6xstlcVhSGuyUcjHF8XV7EnKrtnlhzjVI130_assertion description "[A total of 143 genetic polymorphisms in 13 candidate genes (CYP2B6, CYP2C9, CYP2C19, CYP3A4, CYP3A5, ALDH1A1, ALDH3A1, GSTA1, GSTM1, GSTP1, GSTT1, ABCC2 and ABCC4), possibly involved in the activation, metabolism and transport of CPA, were genotyped using 184 cases who developed either > or =grade 3 leukopenia/neutropenia or > or =grade 2 gastrointestinal toxicity and 219 controls who did not show any ADRs throughout the treatment.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP455475.RALu8wx2WMMh6xstlcVhSGuyUcjHF8XV7EnKrtnlhzjVI130_provenance.
- NP455475.RALu8wx2WMMh6xstlcVhSGuyUcjHF8XV7EnKrtnlhzjVI130_assertion evidence source_evidence_literature NP455475.RALu8wx2WMMh6xstlcVhSGuyUcjHF8XV7EnKrtnlhzjVI130_provenance.
- NP455475.RALu8wx2WMMh6xstlcVhSGuyUcjHF8XV7EnKrtnlhzjVI130_assertion SIO_000772 19696793 NP455475.RALu8wx2WMMh6xstlcVhSGuyUcjHF8XV7EnKrtnlhzjVI130_provenance.
- NP455475.RALu8wx2WMMh6xstlcVhSGuyUcjHF8XV7EnKrtnlhzjVI130_assertion wasDerivedFrom befree-20140225 NP455475.RALu8wx2WMMh6xstlcVhSGuyUcjHF8XV7EnKrtnlhzjVI130_provenance.
- NP455475.RALu8wx2WMMh6xstlcVhSGuyUcjHF8XV7EnKrtnlhzjVI130_assertion wasGeneratedBy ECO_0000203 NP455475.RALu8wx2WMMh6xstlcVhSGuyUcjHF8XV7EnKrtnlhzjVI130_provenance.